Sean P. Pitroda

5.9k total citations · 2 hit papers
94 papers, 3.4k citations indexed

About

Sean P. Pitroda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sean P. Pitroda has authored 94 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 30 papers in Cancer Research. Recurrent topics in Sean P. Pitroda's work include Cancer Immunotherapy and Biomarkers (33 papers), Lung Cancer Treatments and Mutations (22 papers) and Cancer Genomics and Diagnostics (16 papers). Sean P. Pitroda is often cited by papers focused on Cancer Immunotherapy and Biomarkers (33 papers), Lung Cancer Treatments and Mutations (22 papers) and Cancer Genomics and Diagnostics (16 papers). Sean P. Pitroda collaborates with scholars based in United States, Germany and Japan. Sean P. Pitroda's co-authors include Ralph R. Weichselbaum, Nikolai N. Khodarev, Steven J. Chmura, Michael A. Beckett, Donald Küfe, Thomas E. Darga, Dhara MacDermed, Kelli B. Pointer, Hasan Rajabi and Jason J. Luke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Sean P. Pitroda

91 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

2018 434 citations Jason J. Luke, Theodore Karrison et al. profile →
Radiotherapy, immunity, and immune checkpoint inhibitors

2024 58 citations Connor Lynch, Sean P. Pitroda et al. profile →

Peers

Countries citing papers authored by Sean P. Pitroda

Since Specialization

Citations

This map shows the geographic impact of Sean P. Pitroda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean P. Pitroda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean P. Pitroda more than expected).

Fields of papers citing papers by Sean P. Pitroda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean P. Pitroda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean P. Pitroda. The network helps show where Sean P. Pitroda may publish in the future.

Co-authorship network of co-authors of Sean P. Pitroda

This figure shows the co-authorship network connecting the top 25 collaborators of Sean P. Pitroda. A scholar is included among the top collaborators of Sean P. Pitroda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sean P. Pitroda. Sean P. Pitroda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma 2024 ·Clinical and Translational Radiation Oncology ·Daniel Huang, Connor Lynch, (unknown), Randy F. Sweis, Paul J. Chang, Walter M. Stadler, Russell Z. Szmulewitz, Peter H. O’Donnell, Abhinav Sidana, Scott Eggener, Arieh L. Shalhav, Stanley L. Liauw, Sean P. Pitroda	0
2	Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites 2024 ·Clinical Cancer Research ·Yuzhu Hou, Kaiting Yang, Liangliang Wang, Jiaai Wang, Xiaona Huang, András Piffkó, (unknown), Xinshuang Yu, Enyu Rao, (unknown), Jason Bugno, Matthias Mack, Everett E. Vokes, Sean P. Pitroda, Steven J. Chmura, Ralph R. Weichselbaum, Hua Liang	23
3	Clinical and molecular correlates of tumor aneuploidy in metastatic non-small cell lung cancer 2024 ·Scientific Reports ·Liam F. Spurr, Sean P. Pitroda	2
4	Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial–Mesenchymal Transition 2023 ·Clinical Cancer Research ·Rohan Katipally, Sean P. Pitroda, Ralph R. Weichselbaum, Samuel Hellmän	5
5	Concurrent Radiation and Immunotherapy Augments Local Immunity and Improves Survival in Aneuploid NSCLC 2023 ·International Journal of Radiation OncologyBiologyPhysics ·Liam F. Spurr, Carlos Alberto Martínez, Woojin Kang, (unknown), Yuanyuan Zha, (unknown), Stanley I. Gutiontov, (unknown), Connor Lynch, Kelli B. Pointer, Everett E. Vokes, Christine M. Bestvina, Jyoti D. Patel, Maximilian Diehn, Ralph R. Weichselbaum, Steven J. Chmura, Sean P. Pitroda	1
6	A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy 2022 ·npj Precision Oncology ·Liam F. Spurr, Carlos A. Martinez, Rohan Katipally, Soumya Iyer, S. Pugh, John Bridgewater, John Primrose, Enric Domingo, Tim Maughan, Michael I. D’Angelica, Mark S. Talamonti, Mitchell C. Posner, Philip P. Connell, Ralph R. Weichselbaum, Sean P. Pitroda	5
7	The oligometastatic spectrum in the era of improved detection and modern systemic therapy 2022 ·Nature Reviews Clinical Oncology ·Rohan Katipally, Sean P. Pitroda, Aditya Juloori, Steven J. Chmura, Ralph R. Weichselbaum	49
8	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels 2022 ·Annals of Surgical Oncology ·(unknown), Charles C. Vining, (unknown), (unknown), Ardaman Shergill, Hedy L. Kindler, Kevin K. Roggin, Mitchell C. Posner, Osman Ahmed, Stanley L. Liauw, Sean P. Pitroda, Chih‐Yi Liao, Theodore Karrison, Ralph Weichselbaum, Blasé N. Polite, Oliver S. Eng, Daniel V.T. Catenacci, Kiran K. Turaga	3
9	A prospective clinical and transcriptomic feasibility study of oral‐only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity 2021 ·Cancer ·(unknown), P.L. Dorn, Carlos A. Martínez, (unknown), Denise Cloutier, Tatjana Antic, Daniel W. Golden, Theodore Karrison, Sean P. Pitroda, Russell Z. Szmulewitz, Stanley L. Liauw	3
10	Suppression of local type I interferon by gut microbiota–derived butyrate impairs antitumor effects of ionizing radiation 2021 ·The Journal of Experimental Medicine ·Kaiting Yang, Yuzhu Hou, Yuan Zhang, Hua Liang, Anukriti Sharma, Wenxin Zheng, Liangliang Wang, (unknown), K. Tatebe, Steven J. Chmura, Sean P. Pitroda, Jack A. Gilbert, Yang‐Xin Fu, Ralph R. Weichselbaum	85
11	A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study 2021 ·Journal of Thoracic Oncology ·Christine M. Bestvina, Kelli B. Pointer, Theodore Karrison, Hania Al‐Hallaq, Philip C. Hoffman, (unknown), Aditya Juloori, J.M. Melotek, Septimiu Murgu, (unknown), Everett E. Vokes, Ralph R. Weichselbaum, Sean P. Pitroda, Jyoti D. Patel, Steven J. Chmura	77
12	RO01.01 Prospective Evaluation of Ipilimumab and Nivolumab in Patients with Non-Small Cell Lung Cancer Brain Metastasis 2021 ·Journal of Thoracic Oncology ·Aditya Juloori, Christine M. Bestvina, Sean P. Pitroda, Kelli B. Pointer, (unknown), P C Hoffman, Everett E. Vokes, Jyoti D. Patel, Steven J. Chmura	1
13	Multi-Site SBRT and Sequential Pembrolizumab: Treated Metastasis Control and Immune-Related Expression Predict Outcomes 2019 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Jason J. Luke, Sandeep R. Bhave, Theodore Karrison, Paul J. Chang, Yuanyuan Zha, Timothy Carll, Thomas Krausz, Lei Huang, Linda Janisch, (unknown), Nikolai N. Khodarev, R.R. Weichselbaum, Sean P. Pitroda, Steven J. Chmura	5
14	A Validated Radiomics T-cell Score Predicts Response to Multi-site SBRT Combined with Pembrolizumab 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Mark Korpics, Sandeep R. Bhave, Gage Redler, Sean P. Pitroda, (unknown), Steven J. Chmura	3
15	Tumor-reprogrammed resident T cells resist radiation to control tumors 2019 ·Nature Communications ·Ainhoa Arina, Michael A. Beckett, Christian Fernandez, Wenxin Zheng, Sean P. Pitroda, Steven J. Chmura, Jason J. Luke, (unknown), Yuzhu Hou, Byron Burnette, Helena J. Mauceri, Israel Lowy, Tasha N. Sims, Nikolai N. Khodarev, Yang-Xin Fu, Ralph R. Weichselbaum	161
16	Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non–Small Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·Corey C. Foster, Sean P. Pitroda, Ralph R. Weichselbaum	7
17	DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs 2018 ·Cancer Research ·Go Oshima, (unknown), Michael J. Bolt, Alexandre Chlenski, (unknown), Jessica M.S. Jutzy, Neha Biyani, Mitchell C. Posner, Sean P. Pitroda, Ralph R. Weichselbaum, Nikolai N. Khodarev	39
18	JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers 2018 ·Molecular Cancer Therapeutics ·Sean P. Pitroda, Melinda E. Stack, (unknown), (unknown), Lucy Chen, Hua Liang, Akash D. Parekh, Xiaona Huang, Paul D. Roach, Mitchell C. Posner, Ralph R. Weichselbaum, Nikolai N. Khodarev	20
19	Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer 2017 ·Clinical Cancer Research ·Sean P. Pitroda, Riyue Bao, Jorge Andrade, Ralph R. Weichselbaum, Philip P. Connell	13
20	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas 2016 ·Cancer Research ·Audrey Bouillez, Hasan Rajabi, Sean P. Pitroda, Caining Jin, Maroof Alam, Akriti Kharbanda, Ashujit Tagde, Kwok‐Kin Wong, Donald Küfe	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact